Ivosidenib monotherapy in R/R AML resulted in CR/CRh rates of 30%, of which 21% achieved IDH1-MRD clearance, associated with improved DOR (median 11.1 months vs. 6.5 months) and survival (median OS 14.5 months vs. 10.2 months) [83]. The gene discussed is IDH1; the disease is acute myeloid leukemia.